Tanvex BioPharma (TPE:6541) Change In Receivables: NT$-86.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6541 Tanvex BioPharma Inc TPE:6541
41 GF Score
Price NT$37.10
! 3 Warning Signs
View Full Analysis

What is Tanvex BioPharma Change In Receivables?

Tanvex BioPharma TPE:6541 +3.20% 41 Change In Receivables is NT$-86.0 Mil as of Mar. 2026. GuruFocus rates TPE:6541 with a GF Score™ of 41/100. The stock has 3 warning signs investors should review.

Tanvex BioPharma's change in receivables for the quarter that ended in Mar. 2026 was NT$-53.0 Mil. It means Tanvex BioPharma's Accounts Receivable increased by NT$53.0 Mil from Dec. 2025 to Mar. 2026 .

Tanvex BioPharma's change in receivables for the fiscal year that ended in Dec. 2025 was NT$162.0 Mil. It means Tanvex BioPharma's Accounts Receivable declined by NT$162.0 Mil from Dec. 2024 to Dec. 2025 .

Tanvex BioPharma's Accounts Receivable for the quarter that ended in Mar. 2026 was NT$95.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Tanvex BioPharma's Days Sales Outstanding for the three months ended in Mar. 2026 was 65.89.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Tanvex BioPharma's liquidation value for the three months ended in Mar. 2026 was NT$-1,556.6 Mil.

Tanvex BioPharma  (TPE:6541) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Tanvex BioPharma's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=95.906/132.827*91
=65.89

2. In Ben Graham's calculation of liquidation value, Tanvex BioPharma's accounts receivable are only considered to be worth 75% of book value:

Tanvex BioPharma's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=442.241-2273.772+0.75 * 95.906+0.5 * 406.034
=-1,556.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tanvex BioPharma Change In Receivables Related Terms

Tanvex BioPharma Change In Receivables Historical Data

* Premium members only.

The historical data trend for Tanvex BioPharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tanvex BioPharma Change In Receivables Chart

Tanvex BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.97 0.07 -7.09 10.09 161.97

Tanvex BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 194.91 28.48 -92.32 30.90 -53.04
TPE:6541
41GF Score
Tanvex BioPharma Inc TPE:6541
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tanvex BioPharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-86.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of NT$-86.0 Mil mean?
Tanvex BioPharma (TPE:6541) has a Change In Receivables of NT$-86.0 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Tanvex BioPharma and its competitors.
Is Tanvex BioPharma's Change In Receivables too high?
Tanvex BioPharma's current Change In Receivables is NT$-86.0 Mil. Overall, Tanvex BioPharma has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Change In Receivables compare to VRTX and REGN?
Tanvex BioPharma's Change In Receivables of NT$-86.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Tanvex BioPharma and its competitors. Tanvex BioPharma's current Change In Receivables is NT$-86.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Tanvex BioPharma (TPE:6541) has a current Change In Receivables of NT$-86.0 Mil. The current Change In Receivables is NT$-86.0 Mil. Tanvex BioPharma's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Change In Receivables is NT$-86.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tanvex BioPharma Business Description

Address No. 12-2, Shengyi Road, Section 2, 6th Floor, Hsinchu County, Zhubei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
41GF Score

Get the complete analysis for TPE:6541

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$37.10
Price